Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 72 followers
Latest posts
Last updated 2 days ago
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
2 days ago
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
2 days ago
Novartis Phase III data confirm sustained efficacy and long-term safety of oral...
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
2 days ago
Novartis Scemblix® Phase III data first to show superior efficacy with a...
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
2 days ago
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
2 days ago
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G)...
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
2 days ago
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR...
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
2 days ago
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
2 days ago
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing...
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
2 days ago
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data...
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
2 days ago
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline arcticnovartis...
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
11 days ago
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und...
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
11 days ago
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and...